Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and The Netherlands: insights from the ETNA-AF-Europe study
Copyright policy )10.1080/00015385.2020.1746095 , 10.1007/s12471-020-01518-7 , 10.6084/m9.figshare.13536402 , 10.6084/m9.figshare.13536402.v1
https://repository.ubn.ru.nl/handle/2066/233790 , https://repository.ubn.ru.nl/handle/2066/238754 , 2066/233790 , 2268/290919 , 2268/291265 , 10067/1749810151162165141 , 10067/1750190151162165141 , 11568/1140778 , 2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/319156 , 2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/319130
10.1080/00015385.2020.1746095 , 10.1007/s12471-020-01518-7 , 10.6084/m9.figshare.13536402 , 10.6084/m9.figshare.13536402.v1
https://repository.ubn.ru.nl/handle/2066/233790 , https://repository.ubn.ru.nl/handle/2066/238754 , 2066/233790 , 2268/290919 , 2268/291265 , 10067/1749810151162165141 , 10067/1750190151162165141 , 11568/1140778 , 2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/319156 , 2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/319130
Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and The Netherlands: insights from the ETNA-AF-Europe study
Abstract Background Studies on the use of non-vitamin K antagonist oral anticoagulants in unselected patients with atrial fibrillation (AF) show that clinical characteristics and dosing practices differ per region, but lack data on edoxaban. Methods With data from Edoxaban Treatment in routiNe clinical prActice for patients with AF in Europe (ETNA-AF-Europe), a large prospective observational study, we compared clinical characteristics (including the dose reduction criteria for edoxaban: creatinine clearance 15–50 ml/min, weight ≤60 kg, and/or use of strong p‑glycoprotein inhibitors) of patients from Belgium and the Netherlands (BeNe) with those from other European countries (OEC). Results Of all 13,639 patients in ETNA-AF-Europe, 2579 were from BeNe. BeNe patients were younger than OEC patients (mean age: 72.3 vs 73.9 years), and had lower CHA2DS2-VASc (mean: 2.8 vs 3.2) and HAS-BLED scores (mean: 2.4 vs 2.6). Patients from BeNe less often had hypertension (61.6% vs 80.4%), and/or diabetes mellitus (17.3% vs 23.1%) than patients from OEC. Moreover, relatively fewer patients in BeNe were prescribed the reduced dose of 30 mg edoxaban (14.8%) than in OEC (25.4%). Overall, edoxaban was dosed according to label in 83.1% of patients. Yet, 30 mg edoxaban was prescribed in the absence of any dose reduction criteria in 36.9% of 30 mg users (5.5% of all patients) in BeNe compared with 35.5% (9.0% of all patients) in OEC. Conclusion There were several notable differences between BeNe and OEC regarding clinical characteristics and dosing practices in patients prescribed edoxaban, which are relevant for the local implementation of dose evaluation and optimisation. Trial registration NCT02944019; Date of registration 24 October 2016
- Hôpital Civil de Charleroi Belgium
- Université Libre de Bruxelles Belgium
- Amsterdam UMC Netherlands
- University of Pisa Italy
- Vrije Universiteit Brussel Belgium
Cardiac & Cardiovascular Systems, Cardiologie et circulation, Pyridines, Clinical trial, phase IV, Belgium, Atrial Fibrillation, off-label use, Prospective Studies, Human health sciences, 1102 Cardiorespiratory Medicine and Haematology, Pyridines/therapeutic use, Cardiology - Radboud University Medical Center, Netherlands, Europe -- epidemiology, Netherlands -- epidemiology, clinical trial, stroke, Stroke, Clinical trial, Europe, Factor Xa Inhibitors -- therapeutic use, Treatment Outcome, Original Article, haemorrhage, 3201 Cardiovascular medicine and haematology, Life Sciences & Biomedicine, ROUTINE CLINICAL-PRACTICE, management, phase iv, phase IV, trends, anticoagulants, k oral anticoagulants, Atrial Fibrillation -- complications -- drug therapy -- epidemiology, NDU3J18APO (edoxaban), Thiazoles -- therapeutic use, Netherlands/epidemiology, Systèmes cardiovasculaire & respiratoire, Sciences de la santé humaine, WARFARIN, Europe/epidemiology, Radboudumc 16: Vascular damage RIHS: Radboud Institute for Health Sciences, Thromboembolism, Cardiovascular & respiratory systems, Pyridines -- therapeutic use, MANAGEMENT, Belgium -- epidemiology, Off-label use, Humans, ETNA-AF-Europe principal investigators from Belgium and the Netherlands*, K ORAL ANTICOAGULANTS, Factor Xa Inhibitors/therapeutic use, Belgium/epidemiology, Atrial Fibrillation/complications/drug therapy/epidemiology, Aged, Science & Technology, ETNA-AF-Europe principal investigators from Belgium and the Netherlands, Anticoagulants, Off-Label Use, thromboembolism, TRENDS, warfarin, clinical trial, phase IV, Thiazoles, Cardiovascular System & Hematology, Haemorrhage, Thiazoles/therapeutic use, Cardiovascular System & Cardiology, Human medicine, routine clinical-practice, Factor Xa Inhibitors
Cardiac & Cardiovascular Systems, Cardiologie et circulation, Pyridines, Clinical trial, phase IV, Belgium, Atrial Fibrillation, off-label use, Prospective Studies, Human health sciences, 1102 Cardiorespiratory Medicine and Haematology, Pyridines/therapeutic use, Cardiology - Radboud University Medical Center, Netherlands, Europe -- epidemiology, Netherlands -- epidemiology, clinical trial, stroke, Stroke, Clinical trial, Europe, Factor Xa Inhibitors -- therapeutic use, Treatment Outcome, Original Article, haemorrhage, 3201 Cardiovascular medicine and haematology, Life Sciences & Biomedicine, ROUTINE CLINICAL-PRACTICE, management, phase iv, phase IV, trends, anticoagulants, k oral anticoagulants, Atrial Fibrillation -- complications -- drug therapy -- epidemiology, NDU3J18APO (edoxaban), Thiazoles -- therapeutic use, Netherlands/epidemiology, Systèmes cardiovasculaire & respiratoire, Sciences de la santé humaine, WARFARIN, Europe/epidemiology, Radboudumc 16: Vascular damage RIHS: Radboud Institute for Health Sciences, Thromboembolism, Cardiovascular & respiratory systems, Pyridines -- therapeutic use, MANAGEMENT, Belgium -- epidemiology, Off-label use, Humans, ETNA-AF-Europe principal investigators from Belgium and the Netherlands*, K ORAL ANTICOAGULANTS, Factor Xa Inhibitors/therapeutic use, Belgium/epidemiology, Atrial Fibrillation/complications/drug therapy/epidemiology, Aged, Science & Technology, ETNA-AF-Europe principal investigators from Belgium and the Netherlands, Anticoagulants, Off-Label Use, thromboembolism, TRENDS, warfarin, clinical trial, phase IV, Thiazoles, Cardiovascular System & Hematology, Haemorrhage, Thiazoles/therapeutic use, Cardiovascular System & Cardiology, Human medicine, routine clinical-practice, Factor Xa Inhibitors
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).2 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!